LENZ Therapeutics to Host Commercial Day on April 15, 2025
LENZ Therapeutics (Nasdaq: LENZ) has announced a Commercial Day event scheduled for April 15, 2025, from 2:00 p.m. to 4:00 p.m. EST. The event will showcase the company's commercialization strategy and progress towards the potential approval of LNZ100, their innovative aceclidine-based eye drop treatment for presbyopia.
The presentation will feature key updates including:
- Commercialization strategies
- Supply chain and product distribution readiness
- Perspectives from Key Opinion Leaders and Eye Care Professionals
- Additional special guest speakers
A live audio webcast will be accessible through the company's website, with a replay available for 12 months following the event.
LENZ Therapeutics (Nasdaq: LENZ) ha annunciato un evento Commercial Day previsto per 15 aprile 2025, dalle 14:00 alle 16:00 EST. L'evento presenterà la strategia di commercializzazione dell'azienda e i progressi verso la potenziale approvazione di LNZ100, il loro innovativo trattamento a base di aceclidina per le gocce oculari per la presbiopia.
La presentazione includerà aggiornamenti chiave tra cui:
- Strategie di commercializzazione
- Prontezza della catena di approvvigionamento e distribuzione del prodotto
- Prospettive da parte di Leader di Opinione Chiave e Professionisti della Cura degli Occhi
- Altri relatori ospiti speciali
Un webcast audio in diretta sarà accessibile tramite il sito web dell'azienda, con una registrazione disponibile per 12 mesi dopo l'evento.
LENZ Therapeutics (Nasdaq: LENZ) ha anunciado un evento Commercial Day programado para el 15 de abril de 2025, de 2:00 p.m. a 4:00 p.m. EST. El evento mostrará la estrategia de comercialización de la empresa y los avances hacia la posible aprobación de LNZ100, su innovador tratamiento en gotas para los ojos a base de aceclidina para la presbicia.
La presentación incluirá actualizaciones clave que abarcan:
- Estrategias de comercialización
- Preparación de la cadena de suministro y distribución del producto
- Perspectivas de Líderes de Opinión Clave y Profesionales del Cuidado de los Ojos
- Otros oradores invitados especiales
Se podrá acceder a una transmisión de audio en vivo a través del sitio web de la empresa, con una repetición disponible durante 12 meses después del evento.
LENZ Therapeutics (Nasdaq: LENZ)는 2025년 4월 15일 오후 2시부터 4시까지 EST로 예정된 Commercial Day 이벤트를 발표했습니다. 이 이벤트는 회사의 상업화 전략과 노안 치료를 위한 혁신적인 아세클리딘 기반의 안약인 LNZ100의 잠재적 승인에 대한 진행 상황을 보여줄 것입니다.
발표에는 다음과 같은 주요 업데이트가 포함됩니다:
- 상업화 전략
- 공급망 및 제품 배급 준비 상태
- 주요 의견 리더 및 안과 전문가의 관점
- 기타 특별 게스트 연사
실시간 오디오 웹캐스트는 회사 웹사이트를 통해 접근 가능하며, 이벤트 후 12개월 동안 재생할 수 있습니다.
LENZ Therapeutics (Nasdaq: LENZ) a annoncé un événement Commercial Day prévu pour le 15 avril 2025, de 14h00 à 16h00 EST. L'événement mettra en avant la stratégie de commercialisation de l'entreprise et les progrès vers l'approbation potentielle de LNZ100, leur traitement innovant en gouttes oculaires à base d'aceclidine pour la presbytie.
La présentation comprendra des mises à jour clés, notamment:
- Stratégies de commercialisation
- Préparation de la chaîne d'approvisionnement et distribution du produit
- Perspectives de leaders d'opinion clés et de professionnels des soins oculaires
- Autres intervenants invités spéciaux
Un webcast audio en direct sera accessible via le site web de l'entreprise, avec une rediffusion disponible pendant 12 mois après l'événement.
LENZ Therapeutics (Nasdaq: LENZ) hat eine Commercial Day-Veranstaltung für den 15. April 2025 von 14:00 bis 16:00 Uhr EST angekündigt. Die Veranstaltung wird die Kommerzialisierungsstrategie des Unternehmens und den Fortschritt in Richtung potenzieller Genehmigung von LNZ100, ihrer innovativen aceclidin-basierten Augentropfenbehandlung für Presbyopie, präsentieren.
Die Präsentation wird wichtige Updates umfassen, darunter:
- Kommerzialisierungsstrategien
- Bereitschaft der Lieferkette und Produktverteilung
- Perspektiven von Meinungsführern und Augenpflegefachleuten
- Zusätzliche besondere Gastredner
Ein Live-Audio-Webcast wird über die Unternehmenswebsite zugänglich sein, mit einer Wiederholung, die 12 Monate nach der Veranstaltung verfügbar ist.
- None.
- None.
Event to highlight the commercialization strategy and progress towards the potential approval of LNZ100 for the treatment of presbyopia
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that it will host a Commercial Day to highlight the commercialization strategy and progress towards the potential approval of LNZ100 for the treatment of presbyopia. The event will take place on Tuesday, April 15, 2025, from 2:00 p.m. – 4:00 p.m. EST.
The event will include presentations by management to feature key updates as the Company approaches the potential approval and launch of LNZ100, including commercialization strategies, supply chain and product distribution readiness, perspectives from Key Opinion Leader and Eye Care Professionals and additional special guest speakers.
A live audio webcast of the presentation will be available through the link here and on the Events section of the Investor Relations page of the LENZ Therapeutics website at www.LENZ-tx.com. A replay of the webcast will be available on the Company’s website for 12 months following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
When is LENZ Therapeutics hosting its Commercial Day event and what will be discussed?
What is LNZ100 and what condition does it treat?
How can investors access LENZ Therapeutics' Commercial Day presentation?
What makes LNZ100 unique in the presbyopia treatment market?
What stage is LENZ Therapeutics (LENZ) currently in with LNZ100?
